185 related articles for article (PubMed ID: 38252285)
1. Resolution of PTHrP-Mediated Hypercalcemia Following Treatment with Dual BRAF/MEK Inhibition for BRAFV600E-Positive Metastatic Ameloblastoma.
Corbett K; Ruether D; Seiden-Long I; Kline G
Calcif Tissue Int; 2024 Apr; 114(4):444-449. PubMed ID: 38252285
[TBL] [Abstract][Full Text] [Related]
2. Managing stage 4 ameloblastoma with dual BRAF/MEK inhibition: A case report with 8-year clinical follow-up.
Abramson Z; Dayton OL; Drane WE; Mendenhall WM; Kaye FJ
Oral Oncol; 2022 May; 128():105854. PubMed ID: 35447565
[TBL] [Abstract][Full Text] [Related]
3. Association of MDM2 Overexpression in Ameloblastomas with
Tosios KI; Kalogirou EM; Koutlas IG
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396916
[TBL] [Abstract][Full Text] [Related]
4. Expression of parathyroid hormone-related protein in ameloblastomas.
Ohtsuru M
Tokai J Exp Clin Med; 2005 Dec; 30(4):233-9. PubMed ID: 16482944
[TBL] [Abstract][Full Text] [Related]
5. Role of mitogen-activated protein kinases in the induction of parathyroid hormone-related peptide.
Aklilu F; Gladu J; Goltzman D; Rabbani SA
Cancer Res; 2000 Mar; 60(6):1753-60. PubMed ID: 10749150
[TBL] [Abstract][Full Text] [Related]
6. BRAF-V600E expression correlates with ameloblastoma aggressiveness.
Fregnani ER; Perez DE; Paes de Almeida O; Fonseca FP; Soares FA; Castro-Junior G; Alves FA
Histopathology; 2017 Feb; 70(3):473-484. PubMed ID: 27681305
[TBL] [Abstract][Full Text] [Related]
7. Detection and evaluation of the presence of the BRAF V600E mutation in ameloblastomas in an Indian population.
Goes CF; Spadigam A; Dhupar A; Carvalho KM; Cota J; Syed S
Indian J Pathol Microbiol; 2023; 66(2):246-251. PubMed ID: 37077063
[TBL] [Abstract][Full Text] [Related]
8. BRAF V600E and previously unidentified KRAS G12C mutations in odontogenic tumors may affect MAPK activation differently depending on tumor type.
Oh KY; Kim JH; Cho SD; Yoon HJ; Lee JI; Hong SD
Genes Chromosomes Cancer; 2022 Aug; 61(8):481-490. PubMed ID: 35353428
[TBL] [Abstract][Full Text] [Related]
9. Activating FGFR2-RAS-BRAF mutations in ameloblastoma.
Brown NA; Rolland D; McHugh JB; Weigelin HC; Zhao L; Lim MS; Elenitoba-Johnson KS; Betz BL
Clin Cancer Res; 2014 Nov; 20(21):5517-26. PubMed ID: 24993163
[TBL] [Abstract][Full Text] [Related]
10. BRAF V600E-mutated metastatic pediatric Wilms tumor with complete response to targeted RAF/MEK inhibition.
Obasaju P; Shahab S; Dunn E; Rhee DS; Jiang L; Dome JS; Friedman AD; Argani P; Pratilas CA
Cold Spring Harb Mol Case Stud; 2020 Apr; 6(2):. PubMed ID: 32238401
[TBL] [Abstract][Full Text] [Related]
11. High frequency of BRAF V600E mutations in ameloblastoma.
Kurppa KJ; Catón J; Morgan PR; Ristimäki A; Ruhin B; Kellokoski J; Elenius K; Heikinheimo K
J Pathol; 2014 Apr; 232(5):492-8. PubMed ID: 24374844
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of molecular-targeted chemotherapy in ameloblastomas: A systematic review.
Yoithapprabhunath TR; Srichinthu KK; Gupta D; Singh D; Pasupuleti S; Nirmal RM
Indian J Dent Res; 2022; 33(3):323-331. PubMed ID: 36656197
[TBL] [Abstract][Full Text] [Related]
13. Successful treatment with dacarbazine against a parathyroid hormone-related protein-producing melanoma causing hypercalcemia after immune checkpoint inhibitor failure.
Waki Y; Nobeyama Y; Katsumata F; Asahina A
J Dermatol; 2022 Aug; 49(8):792-795. PubMed ID: 35475557
[TBL] [Abstract][Full Text] [Related]
14. Clinical benefit and radiological response with BRAF inhibitor in a patient with recurrent ameloblastoma harboring V600E mutation.
Fernandes GS; Girardi DM; Bernardes JPG; Fonseca FP; Fregnani ER
BMC Cancer; 2018 Sep; 18(1):887. PubMed ID: 30208863
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant BRAF-targeted therapy for ameloblastoma of the mandible: an organ preservation approach.
Grynberg S; Vered M; Shapira-Frommer R; Asher N; Ben-Betzalel G; Stoff R; Steinberg Y; Amariglio N; Greenberg G; Barshack I; Toren A; Yahalom R; Schachter J; Rechavi G; Hirschhorn A; Abebe Campino G
J Natl Cancer Inst; 2024 Apr; 116(4):539-546. PubMed ID: 37966914
[TBL] [Abstract][Full Text] [Related]
16. BRAF inhibitors in BRAF V600E-mutated ameloblastoma: systematic review of rare cases in the literature.
Ebeling M; Scheurer M; Sakkas A; Pietzka S; Schramm A; Wilde F
Med Oncol; 2023 Apr; 40(6):163. PubMed ID: 37115331
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical analysis of BRAF V600E mutation in ameloblastomas.
do Canto AM; da Silva Marcelino BMR; Schussel JL; Wastner BF; Sassi LM; Corrêa L; de Freitas RR; Hasséus B; Kjeller G; Junior CAL; Braz-Silva PH
Clin Oral Investig; 2019 Feb; 23(2):779-784. PubMed ID: 29855709
[TBL] [Abstract][Full Text] [Related]
18. The diagnostic utility of BRAF VE1 mutation-specific immunohistochemistry in ameloblastoma.
Mendez LD; Wolsefer NS; Asa SL; Wasman J; Yoest JM; Stojanov IJ
Mod Pathol; 2022 Nov; 35(11):1570-1577. PubMed ID: 35676332
[TBL] [Abstract][Full Text] [Related]
19. Frequency of BRAF V600E mutation in a group of Thai patients with ameloblastomas.
Lapthanasupkul P; Laosuk T; Ruangvejvorachai P; Aittiwarapoj A; Kitkumthorn N
Oral Surg Oral Med Oral Pathol Oral Radiol; 2021 Nov; 132(5):e180-e185. PubMed ID: 32665205
[TBL] [Abstract][Full Text] [Related]
20. BRAF
Dizdar L; Werner TA; Drusenheimer JC; Möhlendick B; Raba K; Boeck I; Anlauf M; Schott M; Göring W; Esposito I; Stoecklein NH; Knoefel WT; Krieg A
Int J Cancer; 2019 Mar; 144(6):1379-1390. PubMed ID: 30144031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]